サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442863

眼炎症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2023年～2031年）

Ocular Inflammation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 170 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
眼炎症治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2023年～2031年）
出版日: 2024年01月23日
発行: Transparency Market Research
ページ情報: 英文 170 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

眼炎症治療市場 - レポート対象範囲

世界の眼炎症治療市場に関するTMRのレポートでは、過去と現在の成長動向、および2023年～2031年の予測期間中の市場指標の貴重な洞察を得る機会を調査しています。このレポートは、世界の眼炎症治療市場の2017年～2031年の期間の収益を提供し、2023年を基準年、2031年を予測年とみなします。また、2023年～2031年の世界の眼炎症治療市場の複合年間成長率（CAGR %）も提供しています。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、眼炎症治療市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の眼炎症治療市場の競合情勢を詳しく掘り下げています。世界の眼炎症治療市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の眼炎症治療市場企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測（2017年～2031年）

第5章 重要な洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19パンデミックが業界に与える影響

第6章 世界市場の分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療タイプ別（2017年～2031年）
    • コルチコステロイド
    • 抗生物質
    • モノクローナル抗体
    • 免疫抑制剤
    • サイクル麻痺剤
    • 抗ウイルス薬
    • 抗真菌剤
    • 鎮痛剤
  • 市場魅力度：治療タイプ別

第7章 世界市場の分析と予測：疾患タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患タイプ別（2017年～2031年）
    • 前ブドウ膜炎
    • 後部ブドウ膜炎
    • 汎ブドウ膜炎
    • 中間型ブドウ膜炎
    • 上強膜炎/強膜炎
    • 市場魅力度：疾患タイプ別

第8章 世界市場の分析と予測：投与方法別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与方法別（2017年～2031年）
    • 局所
    • 注射
    • 経口
    • その他
  • 市場魅力度：投与方法別

第9章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別（2017年～2031年）
    • 院内薬局
    • 小売薬局
    • オンライン薬局
    • ドラッグストア
  • 市場魅力度：流通チャネル別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別（2017年～2031年）
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東・アフリカ市場の分析と予測

第16章 競合情勢

  • 市場企業：競合マトリクス（企業階層・規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Bausch Health Companies, Inc.
    • Pfizer Inc.
    • Novartis AG
    • AbbVie, Inc.
    • Cipla Inc.
    • AKRON, Inc.
    • EyeGate
    • Alimera Sciences
    • EyePoint Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 02: Global Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 03: Global Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031
  • Table 04: Global Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 05: Global Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Region, 2017 - 2031
  • Table 06: North America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Country, 2017 - 2031
  • Table 07: North America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 08: North America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 9: North America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 10: North America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031
  • Table 11: Europe Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
  • Table 12: Europe Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 13: Europe Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 14: Europe Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 15: Europe Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031
  • Table 16: Asia Pacific Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
  • Table 17: Asia Pacific Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 18: Asia Pacific Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 19: Asia Pacific Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 20: Asia Pacific Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031
  • Table 21: Latin America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
  • Table 22: Latin America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 23: Latin America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 24: Latin America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 25: Latin America Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031
  • Table 26: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017 - 2031
  • Table 27: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017 - 2031
  • Table 28: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Disease Type, 2017 - 2031
  • Table 29: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Mode of Administration, 2017 - 2031
  • Table 30: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017 - 2031

List of Figures

  • Figure 01: Global Ocular Inflammation Treatment Market Size (US$ Mn), by Region, 2022 - 2031
  • Figure 02: Global Ocular Inflammation Treatment Market Revenue (US$ Mn), by Treatment Type, 2022
  • Figure 03: Global Ocular Inflammation Treatment Market Value Share, by Treatment Type, 2022
  • Figure 04: Global Ocular Inflammation Treatment Market Revenue (US$ Mn), by Disease Type, 2022
  • Figure 05: Global Ocular Inflammation Treatment Market Value Share, by Disease Type, 2022
  • Figure 06: Global Ocular Inflammation Treatment Market Revenue (US$ Mn), by Mode of Administration, 2022
  • Figure 07: Global Ocular Inflammation Treatment Market Value Share, by Mode of Administration, 2022
  • Figure 08: Global Ocular Inflammation Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 09: Global Ocular Inflammation Treatment Market Value Share, by Distribution Channel, 2022
  • Figure 10: Global Ocular Inflammation Treatment Market Value Share, by Region, 2022
  • Figure 11: Global Ocular Inflammation Treatment Market Value (US$ Mn) Forecast, 2017 - 2031
  • Figure 12: Global Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 13: Global Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 14: Global Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 15: Global Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 16: Global Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 17: Global Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023-2031
  • Figure 18: Global Ocular Inflammation Treatment Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 19: Global Ocular Inflammation Treatment Market Value Share, by Distribution Channel, 2022
  • Figure 20: Global Ocular Inflammation Treatment Market Value Share Analysis, by Region, 2022 - 2031
  • Figure 21: Global Ocular Inflammation Treatment Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 22: North America Ocular Inflammation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017 - 2031
  • Figure 23: North America Ocular Inflammation Treatment Market Attractiveness Analysis, by Country, 2023 - 2031
  • Figure 24: North America Ocular Inflammation Treatment Market Value Share Analysis, by Country, 2022 - 2031
  • Figure 25: North America Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 26: North America Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 27: North America Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 28: North America Ocular Inflammation Treatment Market Value Share Analysis, by Distribution Channel, 2022 - 2031
  • Figure 29: North America Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023 - 2031
  • Figure 30: North America Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023 - 2031
  • Figure 31: North America Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023 - 2031
  • Figure 32: North America Ocular Inflammation Treatment Market Attractiveness Analysis, by Distribution Channel, 2023 - 2031
  • Figure 33: Europe Ocular Inflammation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017 - 2031
  • Figure 34: Europe Ocular Inflammation Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
  • Figure 35: Europe Ocular Inflammation Treatment Market Value Share Analysis, by Country/Sub-region, 2022 - 2031
  • Figure 36: Europe Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 37: Europe Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 38: Europe Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 39: Europe Ocular Inflammation Treatment Market Value Share Analysis, by Distribution Channel, 2022 - 2031
  • Figure 40: Europe Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023 - 2031
  • Figure 41: Europe Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023 - 2031
  • Figure 42: Europe Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023 - 2031
  • Figure 43: Europe Ocular Inflammation Treatment Market Attractiveness Analysis, by Distribution Channel, 2023 - 2031
  • Figure 44: Asia Pacific Ocular Inflammation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017 - 2031
  • Figure 45: Asia Pacific Ocular Inflammation Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
  • Figure 46: Asia Pacific Ocular Inflammation Treatment Market Value Share Analysis, by Country/Sub-region, 2022 - 2031
  • Figure 47: Asia Pacific Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 48: Asia Pacific Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 49: Asia Pacific Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 50: Asia Pacific Ocular Inflammation Treatment Market Value Share Analysis, by Distribution Channel, 2022 - 2031
  • Figure 51: Asia Pacific Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023 - 2031
  • Figure 52: Asia Pacific Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023 - 2031
  • Figure 53: Asia Pacific Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023 - 2031
  • Figure 54: Asia Pacific Ocular Inflammation Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 55: Latin America Ocular Inflammation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017 - 2031
  • Figure 56: Latin America Ocular Inflammation Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
  • Figure 57: Latin America Ocular Inflammation Treatment Market Value Share Analysis, by Country/Sub-region, 2022 - 2031
  • Figure 58: Latin America Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 59: Latin America Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 60: Latin America Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 61: Latin America Ocular Inflammation Treatment Market Value Share Analysis, by Distribution Channel, 2022 - 2031
  • Figure 62: Latin America Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023 - 2031
  • Figure 63: Latin America Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023 - 2031
  • Figure 64: Latin America Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023 - 2031
  • Figure 65: Latin America Ocular Inflammation Treatment Market Attractiveness Analysis, by Distribution Channel, 2023 - 2031
  • Figure 66: Middle East & Africa Ocular Inflammation Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017 - 2031
  • Figure 67: Middle East & Africa Ocular Inflammation Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023 - 2031
  • Figure 68: Middle East & Africa Ocular Inflammation Treatment Market Value Share Analysis, by Country/Sub-region, 2022 - 2031
  • Figure 69: Middle East & Africa Ocular Inflammation Treatment Market Value Share Analysis, by Treatment Type, 2022 - 2031
  • Figure 70: Middle East & Africa Ocular Inflammation Treatment Market Value Share Analysis, by Disease Type, 2022 - 2031
  • Figure 71: Middle East & Africa Ocular Inflammation Treatment Market Value Share Analysis, by Mode of Administration, 2022 - 2031
  • Figure 72: Middle East & Africa Ocular Inflammation Treatment Market Value Share Analysis, by Distribution Channel, 2022 - 2031
  • Figure 73: Middle East & Africa Ocular Inflammation Treatment Market Attractiveness Analysis, by Treatment Type, 2023 - 2031
  • Figure 74: Middle East & Africa Ocular Inflammation Treatment Market Attractiveness Analysis, by Disease Type, 2023 - 2031
  • Figure 75: Middle East & Africa Ocular Inflammation Treatment Market Attractiveness Analysis, by Mode of Administration, 2023 - 2031
  • Figure 76: Middle East & Africa Ocular Inflammation Treatment Market Attractiveness Analysis, by Distribution Channel, 2023 - 2031
目次
Product Code: TMRGL41027

Ocular Inflammation Treatment Market - Scope of Report

TMR's report on the global ocular inflammation treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global ocular inflammation treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ocular inflammation treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ocular inflammation treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ocular inflammation treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global ocular inflammation treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ocular inflammation treatment market.

The report delves into the competitive landscape of the global ocular inflammation treatment market. Key players operating in the global ocular inflammation treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global ocular inflammation treatment market profiled in this report.

Key Questions Answered in Global ocular inflammation treatment Market Report:

  • What is the sales/revenue generated by ocular inflammation treatment across all regions during the forecast period?
  • What are the opportunities in the global ocular inflammation treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Ocular Inflammation Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global ocular inflammation treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global ocular inflammation treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ocular inflammation treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Ocular Inflammation Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Ocular Inflammation Treatment Market Analysis and Forecast, 2017 - 2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 6.3.1. Corticosteroids
    • 6.3.2. Antibiotics
    • 6.3.3. Monoclonal Antibodies
    • 6.3.4. Immunosppressant
    • 6.3.5. Cycloplegic Agents
    • 6.3.6. Antivirals
    • 6.3.7. Antifungal
    • 6.3.8. Analgesics
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Disease Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Type, 2017 - 2031
    • 7.3.1. Anterior Uveitis
    • 7.3.2. Posterior Uveitis
    • 7.3.3. Pan Uveitis
    • 7.3.4. Intermediate Uveitis
    • 7.3.5. Episcleritis/Scleritis
    • 7.3.6. 7.4 Market Attractiveness, by Disease Type

8. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Mode of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 8.3.1. Topical
    • 8.3.2. Injectable
    • 8.3.3. Oral
    • 8.3.4. Others
  • 8.4. Market Attractiveness, by Mode of Administration

9. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Drug Stores
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Ocular Inflammation Treatment Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017 - 2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Ocular Inflammation Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 11.2.1. Corticosteroids
    • 11.2.2. Antibiotics
    • 11.2.3. Monoclonal Antibodies
    • 11.2.4. Immunosppressant
    • 11.2.5. Cycloplegic Agents
    • 11.2.6. Antivirals
    • 11.2.7. Antifungal
    • 11.2.8. Analgesics
  • 11.3. Market Attractiveness, by Treatment Type
  • 11.4. Market Value Forecast, by Disease Type, 2017 - 2031
    • 11.4.1. Anterior Uveitis
    • 11.4.2. Posterior Uveitis
    • 11.4.3. Pan Uveitis
    • 11.4.4. Intermediate Uveitis
    • 11.4.5. Episcleritis/Scleritis
  • 11.5. Market Attractiveness, by Disease Type
  • 11.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 11.6.1. Topical
    • 11.6.2. Injectable
    • 11.6.3. Oral
    • 11.6.4. Others
  • 11.7. Market Attractiveness, by Mode of Administration
  • 11.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
    • 11.8.4. Drug Stores
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Treatment Type
    • 11.11.2. By Disease Type
    • 11.11.3. By Mode of Administration
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Ocular Inflammation Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 12.2.1. Corticosteroids
    • 12.2.2. Antibiotics
    • 12.2.3. Monoclonal Antibodies
    • 12.2.4. Immunosppressant
    • 12.2.5. Cycloplegic Agents
    • 12.2.6. Antivirals
    • 12.2.7. Antifungal
    • 12.2.8. Analgesics
  • 12.3. Market Attractiveness, by Treatment Type
  • 12.4. Market Value Forecast, by Disease Type, 2017 - 2031
    • 12.4.1. Anterior Uveitis
    • 12.4.2. Posterior Uveitis
    • 12.4.3. Pan Uveitis
    • 12.4.4. Intermediate Uveitis
    • 12.4.5. Episcleritis/Scleritis
  • 12.5. Market Attractiveness, by Disease Type
  • 12.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 12.6.1. Topical
    • 12.6.2. Injectable
    • 12.6.3. Oral
    • 12.6.4. Others
  • 12.7. Market Attractiveness, by Mode of Administration
  • 12.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
    • 12.8.4. Drug Stores
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Treatment Type
    • 12.11.2. By Disease Type
    • 12.11.3. By Mode of Administration
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Ocular Inflammation Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 13.2.1. Corticosteroids
    • 13.2.2. Antibiotics
    • 13.2.3. Monoclonal Antibodies
    • 13.2.4. Immunosppressant
    • 13.2.5. Cycloplegic Agents
    • 13.2.6. Antivirals
    • 13.2.7. Antifungal
    • 13.2.8. Analgesics
  • 13.3. Market Attractiveness, by Treatment Type
  • 13.4. Market Value Forecast, by Disease Type, 2017 - 2031
    • 13.4.1. Anterior Uveitis
    • 13.4.2. Posterior Uveitis
    • 13.4.3. Pan Uveitis
    • 13.4.4. Intermediate Uveitis
    • 13.4.5. Episcleritis/Scleritis
  • 13.5. Market Attractiveness, by Disease Type
  • 13.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 13.6.1. Topical
    • 13.6.2. Injectable
    • 13.6.3. Oral
    • 13.6.4. Others
  • 13.7. Market Attractiveness, by Mode of Administration
  • 13.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
    • 13.8.4. Drug Stores
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Treatment Type
    • 13.11.2. By Disease Type
    • 13.11.3. By Mode of Administration
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Ocular Inflammation Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 14.2.1. Corticosteroids
    • 14.2.2. Antibiotics
    • 14.2.3. Monoclonal Antibodies
    • 14.2.4. Immunosppressant
    • 14.2.5. Cycloplegic Agents
    • 14.2.6. Antivirals
    • 14.2.7. Antifungal
    • 14.2.8. Analgesics
  • 14.3. Market Attractiveness, by Treatment Type
  • 14.4. Market Value Forecast, by Disease Type, 2017 - 2031
    • 14.4.1. Anterior Uveitis
    • 14.4.2. Posterior Uveitis
    • 14.4.3. Pan Uveitis
    • 14.4.4. Intermediate Uveitis
    • 14.4.5. Episcleritis/Scleritis
  • 14.5. Market Attractiveness, by Disease Type
  • 14.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 14.6.1. Topical
    • 14.6.2. Injectable
    • 14.6.3. Oral
    • 14.6.4. Others
  • 14.7. Market Attractiveness, by Mode of Administration
  • 14.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
    • 14.8.4. Drug Stores
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Treatment Type
    • 14.11.2. By Disease Type
    • 14.11.3. By Mode of Administration
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Ocular Inflammation Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Treatment Type, 2017 - 2031
    • 15.2.1. Corticosteroids
    • 15.2.2. Antibiotics
    • 15.2.3. Monoclonal Antibodies
    • 15.2.4. Immunosppressant
    • 15.2.5. Cycloplegic Agents
    • 15.2.6. Antivirals
    • 15.2.7. Antifungal
    • 15.2.8. Analgesics
  • 15.3. Market Attractiveness, by Treatment Type
  • 15.4. Market Value Forecast, by Disease Type, 2017 - 2031
    • 15.4.1. Anterior Uveitis
    • 15.4.2. Posterior Uveitis
    • 15.4.3. Pan Uveitis
    • 15.4.4. Intermediate Uveitis
    • 15.4.5. Episcleritis/Scleritis
  • 15.5. Market Attractiveness, by Disease Type
  • 15.6. Market Value Forecast, by Mode of Administration, 2017 - 2031
    • 15.6.1. Topical
    • 15.6.2. Injectable
    • 15.6.3. Oral
    • 15.6.4. Others
  • 15.7. Market Attractiveness, by Mode of Administration
  • 15.8. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
    • 15.8.4. Drug Stores
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2017 - 2031
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Treatment Type
    • 15.11.2. By Disease Type
    • 15.11.3. By Mode of Administration
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Bausch Health Companies, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Pfizer Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Novartis AG
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. AbbVie, Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Cipla Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. AKRON, Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. EyeGate
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Alimera Sciences
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. EyePoint Pharmaceuticals, Inc.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview